{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:27:29Z","timestamp":1784003249681,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"21-22","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00213-016-4412-9","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T03:37:09Z","timestamp":1472528229000},"page":"3787-3795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor"],"prefix":"10.1007","volume":"233","author":[{"given":"Max","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambros","family":"Chrones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakop","family":"Gevorkyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Macek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"4412_CR1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","volume":"9","author":"GE Alexander","year":"1986","unstructured":"Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357\u2013381","journal-title":"Annu Rev Neurosci"},{"issue":"Suppl 1","key":"4412_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","volume":"75","author":"L Citrome","year":"2014","unstructured":"Citrome L (2014) Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry 75(Suppl 1):21\u201326","journal-title":"J Clin Psychiatry"},{"key":"4412_CR3","first-page":"173","volume":"4","author":"AN Araujo de","year":"2012","unstructured":"de Araujo AN, de Sena EP, de Oliveira IR, Juruena MF (2012) Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf 4:173\u2013180","journal-title":"Drug Healthc Patient Saf"},{"issue":"7","key":"4412_CR4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","volume":"49","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49(7):538\u2013544","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"4412_CR5","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","volume":"266","author":"K Fujishige","year":"1999","unstructured":"Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 266(3):1118\u20131127","journal-title":"Eur J Biochem"},{"key":"4412_CR6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/0091270010381500","volume":"51","author":"S Fukunaga","year":"2011","unstructured":"Fukunaga S, Kusama M, Arnold FL, Ono S (2011) Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol 51:1237\u20131240","journal-title":"J Clin Pharmacol"},{"key":"4412_CR7","doi-asserted-by":"crossref","unstructured":"Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 212:27\u201352","DOI":"10.1007\/978-3-642-25761-2_2"},{"issue":"2","key":"4412_CR8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","volume":"331","author":"SM Grauer","year":"2009","unstructured":"Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331(2):574\u2013590","journal-title":"J Pharmacol Exp Ther"},{"key":"4412_CR9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.acn.2006.05.007","volume":"21","author":"CT Gualtieri","year":"2006","unstructured":"Gualtieri CT, Johnson LG (2006) Reliability and validity of a computerized neurocognitive test battery, CNS vital signs. Arch Clin Neuropsychol 21:623\u2013643","journal-title":"Arch Clin Neuropsychol"},{"key":"4412_CR10","doi-asserted-by":"publisher","unstructured":"Heckman PR, van Duinen MA, Bollen EP, Nishi A, Wennogle LP, Blokland A, Prickaerts J (2016) Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol. doi: 10.1093\/ijnp\/pyw030","DOI":"10.1093\/ijnp\/pyw030"},{"issue":"1","key":"4412_CR11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","volume":"62","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62(1):19\u201328","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"4412_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138161211795049624","volume":"17","author":"J Kehler","year":"2011","unstructured":"Kehler J, Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17(2):137\u2013150","journal-title":"Curr Pharm Des"},{"key":"4412_CR13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.neuro.051508.135422","volume":"32","author":"AC Kreitzer","year":"2009","unstructured":"Kreitzer AC (2009) Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 32:127\u2013147","journal-title":"Annu Rev Neurosci"},{"key":"4412_CR14","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association; Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1\u201356"},{"issue":"9657","key":"4412_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657):31\u201341","journal-title":"Lancet"},{"key":"4412_CR16","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209\u20131223","DOI":"10.1056\/NEJMoa051688"},{"key":"4412_CR17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fpsyg.2014.01301","volume":"5","author":"T Macpherson","year":"2014","unstructured":"Macpherson T, Morita M, Hikida T (2014) Striatal direct and indirect pathways control decision-making behavior. Front Psychol 5:1301","journal-title":"Front Psychol"},{"issue":"1","key":"4412_CR18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79\u2013104","journal-title":"Mol Psychiatry"},{"key":"4412_CR19","doi-asserted-by":"crossref","unstructured":"Miyata A, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B, Ebe K, Noda A, Noda Y, Iritani S, Ozaki N (2015) The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers. Psychopharmacology (Berl) 232(12):2127\u20132137","DOI":"10.1007\/s00213-014-3843-4"},{"issue":"Suppl 1","key":"4412_CR20","first-page":"20","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW (2007) Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 68(Suppl 1):20\u201327","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"4412_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1471-4159.2010.06604.x","volume":"113","author":"E Perez-Costas","year":"2010","unstructured":"Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 113(2):287\u2013302","journal-title":"J Neurochem"},{"issue":"2","key":"4412_CR22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","volume":"105","author":"H Sano","year":"2008","unstructured":"Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008) Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2. J Neurochem 105(2):546\u2013556","journal-title":"J Neurochem"},{"issue":"2","key":"4412_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","volume":"985","author":"TF Seeger","year":"2003","unstructured":"Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985(2):113\u2013126","journal-title":"Brain Res"},{"issue":"2","key":"4412_CR24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","volume":"51","author":"JA Siuciak","year":"2006","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ (2006) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51(2):374\u2013385","journal-title":"Neuropharmacology"},{"issue":"1","key":"4412_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/jn.00503.2005","volume":"95","author":"XJ Song","year":"2006","unstructured":"Song XJ, Wang ZB, Gan Q, Walters ET (2006) cAMP and cGMP contribute to sensory neuron hyperexcitability and hyperalgesia in rats with dorsal root ganglia compression. J Neurophysiol 95(1):479\u2013492","journal-title":"J Neurophysiol"},{"key":"4412_CR26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13803395.2014.928268","volume":"36","author":"EK Stranks","year":"2014","unstructured":"Stranks EK, Crowe SF (2014) The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol 36:691\u2013700","journal-title":"J Clin Exp Neuropsychol"},{"issue":"5","key":"4412_CR27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","volume":"30","author":"DJ Surmeier","year":"2007","unstructured":"Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30(5):228\u2013235","journal-title":"Trends Neurosci"},{"issue":"3","key":"4412_CR28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/jpet.114.218552","volume":"352","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Harada A, Shiraishi E, Kimura H (2015) In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. J Pharmacol Exp Ther 352(3):471\u2013479","journal-title":"J Pharmacol Exp Ther"},{"issue":"Pt 2","key":"4412_CR29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.2044-8260.1987.tb00740.x","volume":"26","author":"N Tarrier","year":"1987","unstructured":"Tarrier N (1987) An investigation of residual psychotic symptoms in discharged schizophrenic patients. Br J Clin Psychol 26(Pt 2):141\u2013143","journal-title":"Br J Clin Psychol"},{"issue":"3","key":"4412_CR30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","volume":"328","author":"S Threlfell","year":"2009","unstructured":"Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009) Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther 328(3):785\u2013795","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-016-4412-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-016-4412-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:36:23Z","timestamp":1498325783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-016-4412-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":30,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1007\/s00213-016-4412-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]}}}